Edesa Biotech Issues Letter to Shareholders
Edesa Biotech Issues Letter to Shareholders Dear Fellow Shareholders, It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our operations. 2020 has been anything but an ordinary year. While Edesa's first full year as a public company brought unexpected challenges, it also brought opportunities to demonstrate the flexibility and breadth of our clinical development strategy. During the past twelve months, despite lock-downs and other pandemic related disruptions, we continue...